SPHERA FUNDS MANAGEMENT LTD. — 13F Portfolio

Sphera Funds Management Ltd. is an Israel-based investment management firm headquartered in Tel Aviv, specializing primarily in the healthcare and life sciences sectors. Founded by Rami Sagi, the firm has established a reputation within global capital markets as a specialist allocator with deep domain expertise in pharmaceutical, biotechnology, and medical technology equities. Sphera files quarterly 13F disclosures with the U.S. Securities and Exchange Commission under CIK #0001496201, reflecting its meaningful allocation to U.S.-listed securities — a natural consequence of the concentration of publicly traded healthcare companies on American exchanges. The firm operates across multiple fund vehicles and serves a predominantly institutional and high-net-worth client base. As a non-U.S. domiciled manager with significant U.S. equity exposure, Sphera occupies a distinctive niche: it brings an international perspective and a specialist research process to a sector that demands deep scientific literacy, regulatory awareness, and an understanding of clinical development timelines. The firm's organizational structure supports both long-only and hedged strategies, allowing it to express conviction across varying market conditions. Investors and allocators seeking to examine Sphera's historical 13F filings can leverage the platform's 13F history tools to trace the evolution of disclosed U.S. positions over multiple quarters.

Sphera Funds Management employs a fundamentally driven, research-intensive investment approach with a pronounced emphasis on the healthcare and life sciences value chain. The firm's core competency lies in evaluating pharmaceutical pipelines, clinical trial data, FDA regulatory pathways, and the commercial potential of therapeutic assets across oncology, rare diseases, immunology, and medical devices. This specialized knowledge enables the team — led by CIO Uri Belenky — to identify asymmetric risk-reward opportunities that generalist managers may overlook or misjudge. The investment style blends elements of growth and growth-at-a-reasonable-price (GARP) investing with event-driven catalysts. Sphera frequently positions around binary clinical events, regulatory milestones, and M&A activity within the biotech and pharma space. The firm also maintains selective exposure to technology and broader sectors where the team identifies compelling fundamental setups, though healthcare remains the dominant allocation pillar. Portfolio construction reflects a willingness to hold concentrated positions in high-conviction names while maintaining diversification across therapeutic areas and market capitalizations. The 13F Portfolio Composition reveals a mix of large-cap pharmaceutical holdings — providing portfolio stability and liquidity — alongside mid-cap and small-cap biotech names where the greatest upside potential and idiosyncratic alpha typically reside. Turnover tends to be moderate to high, consistent with an event-driven overlay that responds to clinical readouts, regulatory decisions, and shifting competitive dynamics within therapeutic categories. The Sector Allocation History observable across quarterly filings underscores Sphera's persistent healthcare overweight, though the precise sub-sector tilts — between pharmaceuticals, biotechnology, medical devices, and healthcare services — shift meaningfully over time in response to the team's assessment of where the most attractive opportunities lie. INVESTMENT RISK PROFILE The risk profile of Sphera Funds Management is shaped fundamentally by its sector concentration in healthcare and life sciences — an industry segment characterized by both idiosyncratic catalysts and systematic exposure to regulatory, political, and scientific risk. Biotech-heavy portfolios are inherently subject to elevated volatility, particularly around binary events such as Phase III clinical trial results, FDA advisory committee meetings, and drug pricing policy developments. The Max Drawdown Depth for a portfolio with Sphera's characteristics can be significant during periods of sector-wide dislocation. Notable stress episodes for healthcare-focused managers have included the 2015-2016 drug pricing controversy, the broader biotech correction of late 2021 into 2022, and intermittent periods of risk-off sentiment that disproportionately affect smaller-capitalization biotech equities. The firm's inclusion of large-cap pharma names likely provides a partial buffer during such episodes, though concentration risk remains an inherent feature of the strategy. From a Volatility Profile perspective, Sphera's disclosed portfolio would be expected to exhibit higher standard deviation than a broad-market benchmark, given the beta characteristics of biotech and pharmaceutical equities. However, the firm's hedging capabilities — consistent with its hedge fund structure — may mitigate realized portfolio volatility beyond what is visible in the long-only 13F disclosure. Allocators should recognize that 13F filings capture only the U.S. long equity book and do not reflect short positions, options overlays, non-U.S. holdings, or other risk management instruments that Sphera may employ. Liquidity risk is another relevant consideration. Smaller-capitalization biotech names can experience thin trading volumes, particularly in periods of market stress, which may amplify drawdowns and complicate position management. The mix of large-cap and small-cap holdings visible in filings suggests Sphera manages this risk through deliberate position sizing across the liquidity spectrum. The platform's backtesting service and portfolio simulator tools can help approximate the historical risk-adjusted outcomes of Sphera's disclosed long positions, though users should account for the inherent limitations of 13F-only analysis.

Sphera Funds Management Ltd. presents a clearly differentiated profile within the universe of 13F-filing investment managers. Its deep specialization in healthcare and life sciences, combined with an Israel-based operational hub and a global investment mandate, positions it as a niche allocator with genuine domain expertise rather than a generalist with a sector tilt. The firm's filings reveal a portfolio driven by fundamental conviction, clinical catalyst awareness, and a willingness to hold concentrated positions across the market-capitalization spectrum. Key analytical observations include the persistent healthcare sector overweight, the blend of defensive large-cap pharma and higher-beta biotech exposure, and the moderate-to-high turnover rate that reflects an active, event-driven approach. The Sharpe Ratio achievable through this strategy is likely to be episodic — potentially strong during favorable biotech cycles and compressed during sector drawdowns — making regime sensitivity a critical consideration for allocators evaluating Sphera's capital trajectory. The Annualized Return (CAGR) derived from replicating Sphera's disclosed positions over time would provide meaningful insight into the firm's stock selection skill within healthcare, though any such analysis must be contextualized by the limitations of 13F data and the absence of hedging, international holdings, and cash management from the disclosed picture. A central diagnostic question for allocators examining Sphera's compounding behavior: How does the firm's capital trajectory respond to shifts in the biotech funding cycle — specifically, does performance exhibit meaningful sensitivity to changes in IPO and secondary offering volumes within life sciences, and does the portfolio's risk-reward profile degrade during prolonged periods of contraction in biotech venture capital and public market issuance?